Suppr超能文献

从临床角度解读群体药代动力学-药效学分析。

Interpreting population pharmacokinetic-pharmacodynamic analyses - a clinical viewpoint.

机构信息

School of Pharmacy, University of Otago, PO Box 56, Dunedin 9054, New Zealand.

出版信息

Br J Clin Pharmacol. 2011 Jun;71(6):807-14. doi: 10.1111/j.1365-2125.2010.03891.x.

Abstract

The population analysis approach is an important tool for clinical pharmacology in aiding the dose individualization of medicines. However, due to their statistical complexity the clinical utility of population analyses is often overlooked. One of the key reasons to conduct a population analysis is to investigate the potential benefits of individualization of drug dosing based on patient characteristics (termed covariate identification). The purpose of this review is to provide a tool to interpret and extract information from publications that describe population analysis. The target audience is those readers who are aware of population analyses but have not conducted the technical aspects of an analysis themselves. Initially we introduce the general framework of population analysis and work through a simple example with visual plots. We then follow-up with specific details on how to interpret population analyses for the purpose of identifying covariates and how to interpret their likely importance for dose individualization.

摘要

群体分析方法是临床药理学中辅助个体化用药的重要工具。然而,由于其统计学的复杂性,群体分析的临床实用性往往被忽视。进行群体分析的一个主要原因是研究基于患者特征的药物剂量个体化的潜在益处(称为协变量识别)。本综述的目的是提供一种工具,用于解释和提取描述群体分析的出版物中的信息。目标读者是那些已经了解群体分析但尚未自己进行分析技术方面的读者。我们首先介绍群体分析的一般框架,并通过可视化图进行简单示例。然后,我们将详细介绍如何解释群体分析以识别协变量,以及如何解释它们对剂量个体化的可能重要性。

相似文献

1
Interpreting population pharmacokinetic-pharmacodynamic analyses - a clinical viewpoint.
Br J Clin Pharmacol. 2011 Jun;71(6):807-14. doi: 10.1111/j.1365-2125.2010.03891.x.
2
Understanding the time course of pharmacological effect: a PKPD approach.
Br J Clin Pharmacol. 2011 Jun;71(6):815-23. doi: 10.1111/j.1365-2125.2011.03925.x.
3
A Critique of Pharmacokinetic Calculators for Drug Dosing Individualization.
Eur J Drug Metab Pharmacokinet. 2020 Apr;45(2):157-162. doi: 10.1007/s13318-019-00589-1.
4
Dose individualization in PharmDIS-e+.
Int J Clin Pharmacol Ther. 2003 Oct;41(10):451-8. doi: 10.5414/cpp41451.
5
Translating Pharmacokinetic and Pharmacodynamic Data into Practice.
Vet Clin North Am Exot Anim Pract. 2018 May;21(2):169-182. doi: 10.1016/j.cvex.2018.01.001.
7
The integration of pharmacokinetics and pharmacodynamics: understanding dose-response.
Annu Rev Pharmacol Toxicol. 2004;44:111-36. doi: 10.1146/annurev.pharmtox.44.101802.121347.
8
Integrated pharmacokinetics and pharmacodynamics in drug development.
Clin Pharmacokinet. 2007;46(9):713-37. doi: 10.2165/00003088-200746090-00001.
9
Individualization of drug therapy: history, present state, and opportunities for the future.
Clin Pharmacol Ther. 2012 Oct;92(4):458-66. doi: 10.1038/clpt.2012.113. Epub 2012 Sep 5.

引用本文的文献

2
Donanemab exposure-response in early symptomatic Alzheimer's disease.
Alzheimers Dement. 2025 Jul;21(7):e70491. doi: 10.1002/alz.70491.
3
Evaluation of pharmacokinetics of intravenous protein C concentrate in protein C deficiency: implications for treatment initiation and maintenance.
Res Pract Thromb Haemost. 2025 Apr 19;9(3):102859. doi: 10.1016/j.rpth.2025.102859. eCollection 2025 Mar.
4
Population pharmacokinetics of bedaquiline: a systematic review.
Eur J Clin Pharmacol. 2025 Mar;81(3):347-363. doi: 10.1007/s00228-024-03788-1. Epub 2025 Jan 8.
6
Dose Individualisation of Antimicrobials from a Pharmacometric Standpoint: The Current Landscape.
Drugs. 2024 Oct;84(10):1167-1178. doi: 10.1007/s40265-024-02084-7. Epub 2024 Sep 6.
9
Population pharmacokinetic analysis for dose regimen optimization of vancomycin in Southern Chinese children.
CPT Pharmacometrics Syst Pharmacol. 2024 Jul;13(7):1201-1213. doi: 10.1002/psp4.13151. Epub 2024 Apr 30.

本文引用的文献

1
Understanding the time course of pharmacological effect: a PKPD approach.
Br J Clin Pharmacol. 2011 Jun;71(6):815-23. doi: 10.1111/j.1365-2125.2011.03925.x.
2
Statisticians and pharmacokineticists: what they can still learn from each other.
Clin Pharmacol Ther. 2010 Sep;88(3):328-34. doi: 10.1038/clpt.2010.128. Epub 2010 Jul 7.
3
Clinical trial simulation: a review.
Clin Pharmacol Ther. 2010 Aug;88(2):166-82. doi: 10.1038/clpt.2010.114. Epub 2010 Jul 7.
5
Ethnic differences in the population pharmacokinetics and pharmacodynamics of warfarin.
J Pharmacokinet Pharmacodyn. 2010 Feb;37(1):3-24. doi: 10.1007/s10928-009-9138-4. Epub 2009 Nov 26.
6
The time course of drug effects.
Pharm Stat. 2009 Jul-Sep;8(3):176-85. doi: 10.1002/pst.393.
7
Development of a sufficient design for estimation of fluconazole pharmacokinetics in people with HIV infection.
Br J Clin Pharmacol. 2008 Oct;66(4):455-66. doi: 10.1111/j.1365-2125.2008.03247.x. Epub 2008 Jun 28.
8
Pharmacometrics and the transition to model-based development.
Clin Pharmacol Ther. 2007 Aug;82(2):137-42. doi: 10.1038/sj.clpt.6100270.
9
Once-daily enoxaparin in pediatric thromboembolism: a dose finding and pharmacodynamics/pharmacokinetics study.
J Thromb Haemost. 2007 Sep;5(9):1985-7. doi: 10.1111/j.1538-7836.2007.02624.x. Epub 2007 May 21.
10
Model-based drug development.
Clin Pharmacol Ther. 2007 Jul;82(1):21-32. doi: 10.1038/sj.clpt.6100235. Epub 2007 May 23.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验